- Home
- BTMD vs CLLS Comparison
BTMD vs CLLS Comparison
Compare BTMD & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- CLLS
- Stock Information
- Founded
- BTMD 2012
- CLLS 1999
- Country
- BTMD United States
- CLLS France
- Employees
- BTMD N/A
- CLLS N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- CLLS Health Care
- Exchange
- BTMD Nasdaq
- CLLS Nasdaq
- Market Cap
- BTMD 127.8M
- CLLS 143.4M
- IPO Year
- BTMD N/A
- CLLS 2007
- Fundamental
- Price
- BTMD $4.02
- CLLS $1.83
- Analyst Decision
- BTMD Strong Buy
- CLLS Buy
- Analyst Count
- BTMD 1
- CLLS 1
- Target Price
- BTMD $8.00
- CLLS $4.00
- AVG Volume (30 Days)
- BTMD 119.6K
- CLLS 128.3K
- Earning Date
- BTMD 08-07-2025
- CLLS 08-05-2025
- Dividend Yield
- BTMD N/A
- CLLS N/A
- EPS Growth
- BTMD 201.68
- CLLS N/A
- EPS
- BTMD 0.60
- CLLS N/A
- Revenue
- BTMD $199,379,000.00
- CLLS $54,747,000.00
- Revenue This Year
- BTMD $5.87
- CLLS $48.52
- Revenue Next Year
- BTMD $8.59
- CLLS $5.17
- P/E Ratio
- BTMD $6.75
- CLLS N/A
- Revenue Growth
- BTMD 6.44
- CLLS 351.26
- 52 Week Low
- BTMD $3.04
- CLLS $1.10
- 52 Week High
- BTMD $8.35
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- BTMD 49.75
- CLLS 60.54
- Support Level
- BTMD $3.92
- CLLS $1.85
- Resistance Level
- BTMD $4.25
- CLLS $2.36
- Average True Range (ATR)
- BTMD 0.21
- CLLS 0.16
- MACD
- BTMD -0.02
- CLLS 0.04
- Stochastic Oscillator
- BTMD 22.73
- CLLS 48.06
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.